British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

GSK PLC closed 16.45% short of its 52-week high of £16.79, which the company reached on September 9th.

GSK (GSK) stock in focus as the FDA staff raise safety concerns over Blenrep combo for multiple myeloma ahead of an AdCom ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug ...

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug ...

GSK PLC closed 16.09% below its 52-week high of £16.79, which the company achieved on September 9th.

Prefilled syringe presentation offers a convenient administration option to healthcare professionals·         An estimated one million people develop shingles in the US each year[1]GSK plc ...

FDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.

GSK announced on Thursday that it has received approval from the US Food and Drug Administration for a new prefilled syringe presentation of its shingles vaccine, Shingrix.

(Alliance News) - GSK PLC on Thursday said the prefilled syringe version of its vaccine Shingrix has been approved for use in the US for the prevention of shingles.

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for a prefilled syringe presentation of Shingrix (GSK's Recombinant Zoster Vaccine or RZV) for the prevention ...